Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1998-01-08
2000-12-26
Adams, Donald E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241861, 4241881, 4241921, 4241941, 435 697, 530350, 530365, A61K 3900, A61K 3921, C12P 2104, C07K 1400
Patent
active
061654701
ABSTRACT:
Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.
REFERENCES:
patent: 4336248 (1982-06-01), Bonhard et al.
patent: 4914027 (1990-04-01), Knapp et al.
patent: 4970300 (1990-11-01), Fulton
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5302697 (1994-04-01), Goodey et al.
patent: 5336603 (1994-08-01), Capon et al.
Capon et al., Designing CD4 immunoadhesins for AIDS therapy, Nature, 337:525-531 (1989).
Reed et al., Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin, Chem. Abst. vol. 109, Abst. No. 227803q (1988).
Ogino et al., Chemical modification of superoxide dismutase, Chem. Abstr. vol. 109, Abst. No. 163477u (1988).
Clement et al., Expression in E. Coli of a MalE-CD4 hybrid protein which is purified in one step and neutralizes the HIV virus in vitro, C.R. Acad. Sci. Paris (Series III) 308:401-406 (1989).
Hammarberg et al., Dual affinity fusion approach and its use to express recombinant human insulin-like growth factor II, Proc. Natl. Acad. Sci. (USA) 86:4367-4371 (1989).
Semba et al., A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma, Proc. Natl. Acad. Sci. (USA), vol. 82-6497-6501 (1985).
Simmons et al., The Fc-gamma receptor of natural killer cells is a phospolipid-linked membrane protein, Nature, 333:568-570 (1988).
Berger et al., A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus, Proc. Natl. Acad. Sci. 85;2357-2361 (1988).
Jameson et al., Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein, Science 240;1335-1339 (1988).
Traunecker et al., Soluble CD4 molecules neutralize human immunodeficiency virus type 1, Nature 331; 84-86 (1988).
Hu et al., Protection of macaques against siv infection by subunit vaccines of siv envelope glycoprotein gp 160, Science 255;456-459 (1992).
Bolognesi (1989) Science 246, 1233-1234.
Becquart Jerome
Fleer Reinhard
Hirel Philippe
Klatzmann David
Landais Didier
Adams Donald E.
Ponnalun P.
Rhone-Poulenc
LandOfFree
Albumin derivatives with therapeutic functions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Albumin derivatives with therapeutic functions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Albumin derivatives with therapeutic functions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-991747